Ankeet Bhatt, MD, MBA provides additional perspective on a recent study examining the cost-effectiveness and health impact of sacubitril/valsartan use at different thresholds of ejection fraction.
Data from a phase 1b trial presented at HFSA 2023 detail the effects of JK07, an investigational agent from Salubris Biotherapeutics, in patients with heart failure with reduced ejection fraction.
A study presented at HFSA 2023 offers clinicians an overview of the influence of socioeconomic status on access to implantable hemodynamic monitors using the National Inpatient Sample.
Announced on October 9, the decision to issue a CRL is based on the FDA's belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established.
Hosts are joined by Marat Fudim, MD, MHS, of Duke, to discuss the REBALANCE-HF trial, which examined endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction.
The REBALANCE-HF trial at HFSA 2023 reveals that right greater splanchnic nerve ablation was well-tolerated and safe in patients with HFpEF, with additional analysis shedding light on the proportion of responders to the procedure.
Anand Shah, MD, MBA, provides insights into a study he led examining the impact of out-of-pocket costs and insurance type on uptake of GDMT in patients with heart failure with reduced ejection fraction.
A propensity score-matched analysis of data suggests use of spironolactone could reduce the 3-year risk of developing Alzheimer disease or dementia among patients with heart failure with reduced ejection fraction.
José López, MD, discusses the results of a study he led examining contemporary trends in racial disparities as it pertains to LVAD utilization in patients with heart failure with reduced ejection fraction.
Muthiah Vaduganathan, MD, MPH, offers insight and perspective into a new annual report from the Heart Failure Society of America outlining trends in epidemiology and outcomes in heart failure.
In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.
Shaquille O'Neal and Elizabeth Ofili, MD, sit down to discuss Shaq Gets Real, which is a new campaign from Arbor Pharmaceuticals to increase awareness of the disparities in heart failure rates in the African American community.